Clearmind’s CMND‑100 Delivers Consistent Safety in Alcohol Use Disorder Trial

Key Points

• CMND‑100 has been well tolerated across several dosing groups, including higher doses, with no serious adverse events reported.
• An independent safety board has repeatedly reviewed the data and supported moving the trial forward into new dose levels.
• The study is enrolling people with moderate to severe Alcohol Use Disorder to evaluate safety, how the drug behaves in the body, and early signs of benefit.

Clearmind Medicine Inc. (Nasdaq: CMND) oral drug candidate CMND‑100 continues to show a strong safety profile in an ongoing Phase I/IIa study for Alcohol Use Disorder, with no serious side effects reported across multiple patient groups. The company describes CMND‑100 as a non‑hallucinogenic therapy designed to help people with moderate to severe alcohol problems reduce drinking and cravings.

Safety results across multiple dosing cohorts

In each dosing cohort of the trial, participants have been able to continue CMND‑100 treatment without stopping due to safety concerns. Reported side effects have generally been mild, and no serious complications have appeared that would force a pause or redesign of the study. This consistent experience across different dose levels suggests that CMND‑100 can be administered safely while researchers work to identify the most effective dose range.

 Oversight from an independent safety monitoring board

An independent data and safety monitoring board regularly reviews unblinded safety data from the trial. After each review, the board has recommended that the study continue and advance to higher‑dose cohorts, indicating confidence in the overall safety profile to date. This external oversight adds credibility to the findings and helps ensure that patient protection remains front‑and‑center as the program advances.

 How CMND‑100 is designed to address Alcohol Use Disorder

CMND‑100 is intended to act on brain circuits involved in addiction and alcohol craving while avoiding the hallucinogenic effects seen with classic psychedelics. The aim is to provide a medicine that people can take in everyday clinical settings as part of longer‑term treatment, rather than a therapy limited to supervised, one‑time sessions. By targeting both drinking behavior and the urge to drink, CMND‑100 seeks to address key drivers of Alcohol Use Disorder.

 Implications for Clearmind and CMND shareholders

The consistent safety data reduce early‑stage risk for Clearmind’s lead program and support the decision to keep moving toward larger studies focused on effectiveness. If upcoming results show clear reductions in alcohol use and craving, CMND‑100 could emerge as a new treatment option in a field where many patients struggle to find therapies that fit their lives and are tolerable over time.